Artivion Receives FDA Approval for Nexus Aortic Arch System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Artivion announced that the FDA has approved the premarket approval application, or PMA, for the Nexus Aortic Arch System, developed by Endospan, Artivion's partner. The approval entitles Artivion to exercise its option to acquire Endospan at any time within 90 days of receiving this notice of FDA approval. Artivion has a $150M delayed draw term loan in place, secured in anticipation of this approval, to fund a potential acquisition. The company is working to complete its evaluation of the option following the earlier than anticipated approval. Nexus is a branched endovascular stent graft system approved in the U.S. for the minimally invasive treatment of aortic arch disease, including chronic aortic dissections. The FDA's approval is supported by data from the Nexus TRIOMPHE IDE trial, which demonstrated 90% patient survival from lesion-related death, 90% freedom from disabling stroke at 1-year post treatment, and 98% freedom from reintervention due to endoleaks at one year in a high-risk patient population.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AORT
Wall Street analysts forecast AORT stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.570
Low
40.00
Averages
51.71
High
58.00
Current: 22.570
Low
40.00
Averages
51.71
High
58.00
About AORT
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons in treating patients with aortic diseases. The Company operates through two segments, which include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other products. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products. It is engaged in the endovascular repair of aortic arch disease and the developer of the NEXUS Aortic Arch System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Artivion Completes Acquisition of Endospan to Expand Aortic Product Line
- Acquisition Completed: Artivion has finalized its acquisition of Endospan for $135 million, funded through a previously secured $150 million delayed draw term loan, thereby solidifying its market leadership in aortic disease treatment.
- FDA Approval: The NEXUS branched endovascular stent graft system received FDA premarket approval in April 2026, marking a significant technological advancement for Artivion in treating aortic arch disease, which is expected to drive future sales growth.
- Enhanced Product Portfolio: This acquisition positions Artivion as the only company globally with a complete portfolio of aortic arch solutions, combining the NEXUS system with AMDS and ARCEVO LSA, thereby increasing its competitive edge to meet the growing patient demand.
- Platform Technology Expansion: The NEXUS system represents not just a single product but a platform technology, allowing Artivion to add a robust pipeline of next-generation aortic arch technologies currently in development, which is anticipated to further strengthen its leadership position in the market.
See More
Artivion Completes Acquisition of Endospan, Enhancing Aortic Solutions Portfolio
- Acquisition Finalized: Artivion, Inc. has completed the acquisition of Endospan for $175 million, plus up to $200 million contingent on the future U.S. commercial performance of the NEXUS system, marking a significant strategic milestone in complex aortic pathologies.
- FDA Approval Drives Market: The NEXUS® Aortic Arch System received FDA PMA approval in April 2026, becoming the first off-the-shelf endovascular solution for high-risk patients, which is expected to significantly enhance Artivion's competitiveness in the aortic treatment market.
- Global Market Integration: This acquisition integrates the NEXUS system into Artivion's global portfolio, strengthening its market position in Europe, Asia-Pacific, and Latin America, thereby further expanding Artivion's leadership in international markets.
- Platform Technology Expansion: NEXUS is not just a single product but a platform technology; through this acquisition, Artivion will enrich its pipeline of next-generation aortic arch technologies, solidifying its leadership position in the aortic arch market over time.
See More
Yarger Wealth Strategies Acquires Significant Stake in Artivion
- New Position Disclosure: On May 13, 2026, Yarger Wealth Strategies, LLC disclosed a new position by acquiring 634,223 shares of Artivion, valued at approximately $25.02 million, indicating strong confidence in the company's prospects.
- Significant Holding Proportion: This acquisition makes Artivion the largest holding in the fund, comprising 9.35% of its reportable assets, which total $248.43 million, reflecting optimism about the company's future growth potential.
- Market Performance Analysis: As of May 15, 2026, Artivion's stock price stood at $22.77, down 21.4% year-over-year, significantly underperforming the S&P 500 by 46.6 percentage points, suggesting market caution regarding its outlook.
- Investment Strategy Shift: Yarger Wealth Strategies primarily invests in ETFs, and this substantial increase in Artivion shares marks a significant shift in its investment strategy, demonstrating confidence in the long-term potential of the company within the cardiovascular medical device sector.
See More
Yarger Wealth Strategies Acquires Major Stake in Artivion
- New Position Disclosure: On May 13, 2026, Yarger Wealth Strategies, LLC disclosed a new position by acquiring 634,223 shares of Artivion, estimated at $25.02 million, indicating strong confidence in the company.
- Significant Holding: This acquisition makes Artivion the largest holding in Yarger Wealth Strategies' portfolio, comprising 9.35% of its $248.43 million reportable assets, highlighting its importance in the investment strategy.
- Poor Market Performance: As of May 15, 2026, Artivion shares were priced at $22.77, down 21.4% over the past year and trailing the S&P 500 by 46.6 percentage points, reflecting market concerns about its future growth.
- Investor Confidence Test: Despite Artivion's poor stock performance, Yarger Wealth Strategies chose to increase its stake during this downturn, demonstrating confidence in the company's long-term potential in the cardiovascular medical device sector.
See More
Artivion Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Ademi LLP is investigating Artivion for potential securities fraud due to possibly inaccurate statements regarding its financial statements, business operations, and prospects, which could lead to investor losses.
- Decline in Stent Sales: On May 7, 2026, Artivion acknowledged that international stent sales were lower due to supply chain challenges, which may further impact the company's financial performance and market confidence.
- Increased Legal Risks: The investigation could result in legal lawsuits and liability for Artivion, potentially affecting its stock price and investor confidence, thereby increasing operational uncertainty for the company.
- Investor Attention: Ademi LLP's offer for no-cost investigation participation indicates rising investor interest in Artivion, which may prompt more shareholders to question the company's governance and transparency.
See More
Artivion to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Artivion, Inc. will release its Q1 2026 financial results on May 7, 2026, after market close, providing critical financial and statistical information for investor analysis.
- Teleconference Details: The company will hold a teleconference on the release day at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin, aimed at discussing financial results in depth and addressing investor questions.
- Replay Access: A replay of the teleconference will be available approximately one hour after the event, accessible by calling 877-660-6853 or 201-612-7415, with the replay conference number being 13759187, ensuring that investors who missed the live session can still obtain relevant information.
- Company Background: Artivion is a medical device company focused on cardiac and vascular surgery, offering products such as aortic stent grafts and surgical sealants, operating in over 100 countries, and dedicated to providing solutions for the challenges faced by surgeons treating aortic diseases.
See More
Artivion Completes Acquisition of Endospan to Expand Aortic Product Line
- Acquisition Completed: Artivion has finalized its acquisition of Endospan for $135 million, funded through a previously secured $150 million delayed draw term loan, thereby solidifying its market leadership in aortic disease treatment.
- FDA Approval: The NEXUS branched endovascular stent graft system received FDA premarket approval in April 2026, marking a significant technological advancement for Artivion in treating aortic arch disease, which is expected to drive future sales growth.
- Enhanced Product Portfolio: This acquisition positions Artivion as the only company globally with a complete portfolio of aortic arch solutions, combining the NEXUS system with AMDS and ARCEVO LSA, thereby increasing its competitive edge to meet the growing patient demand.
- Platform Technology Expansion: The NEXUS system represents not just a single product but a platform technology, allowing Artivion to add a robust pipeline of next-generation aortic arch technologies currently in development, which is anticipated to further strengthen its leadership position in the market.
See More
Artivion Completes Acquisition of Endospan, Enhancing Aortic Solutions Portfolio
- Acquisition Finalized: Artivion, Inc. has completed the acquisition of Endospan for $175 million, plus up to $200 million contingent on the future U.S. commercial performance of the NEXUS system, marking a significant strategic milestone in complex aortic pathologies.
- FDA Approval Drives Market: The NEXUS® Aortic Arch System received FDA PMA approval in April 2026, becoming the first off-the-shelf endovascular solution for high-risk patients, which is expected to significantly enhance Artivion's competitiveness in the aortic treatment market.
- Global Market Integration: This acquisition integrates the NEXUS system into Artivion's global portfolio, strengthening its market position in Europe, Asia-Pacific, and Latin America, thereby further expanding Artivion's leadership in international markets.
- Platform Technology Expansion: NEXUS is not just a single product but a platform technology; through this acquisition, Artivion will enrich its pipeline of next-generation aortic arch technologies, solidifying its leadership position in the aortic arch market over time.
See More
Yarger Wealth Strategies Acquires Significant Stake in Artivion
- New Position Disclosure: On May 13, 2026, Yarger Wealth Strategies, LLC disclosed a new position by acquiring 634,223 shares of Artivion, valued at approximately $25.02 million, indicating strong confidence in the company's prospects.
- Significant Holding Proportion: This acquisition makes Artivion the largest holding in the fund, comprising 9.35% of its reportable assets, which total $248.43 million, reflecting optimism about the company's future growth potential.
- Market Performance Analysis: As of May 15, 2026, Artivion's stock price stood at $22.77, down 21.4% year-over-year, significantly underperforming the S&P 500 by 46.6 percentage points, suggesting market caution regarding its outlook.
- Investment Strategy Shift: Yarger Wealth Strategies primarily invests in ETFs, and this substantial increase in Artivion shares marks a significant shift in its investment strategy, demonstrating confidence in the long-term potential of the company within the cardiovascular medical device sector.
See More
Yarger Wealth Strategies Acquires Major Stake in Artivion
- New Position Disclosure: On May 13, 2026, Yarger Wealth Strategies, LLC disclosed a new position by acquiring 634,223 shares of Artivion, estimated at $25.02 million, indicating strong confidence in the company.
- Significant Holding: This acquisition makes Artivion the largest holding in Yarger Wealth Strategies' portfolio, comprising 9.35% of its $248.43 million reportable assets, highlighting its importance in the investment strategy.
- Poor Market Performance: As of May 15, 2026, Artivion shares were priced at $22.77, down 21.4% over the past year and trailing the S&P 500 by 46.6 percentage points, reflecting market concerns about its future growth.
- Investor Confidence Test: Despite Artivion's poor stock performance, Yarger Wealth Strategies chose to increase its stake during this downturn, demonstrating confidence in the company's long-term potential in the cardiovascular medical device sector.
See More
Artivion Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Ademi LLP is investigating Artivion for potential securities fraud due to possibly inaccurate statements regarding its financial statements, business operations, and prospects, which could lead to investor losses.
- Decline in Stent Sales: On May 7, 2026, Artivion acknowledged that international stent sales were lower due to supply chain challenges, which may further impact the company's financial performance and market confidence.
- Increased Legal Risks: The investigation could result in legal lawsuits and liability for Artivion, potentially affecting its stock price and investor confidence, thereby increasing operational uncertainty for the company.
- Investor Attention: Ademi LLP's offer for no-cost investigation participation indicates rising investor interest in Artivion, which may prompt more shareholders to question the company's governance and transparency.
See More
Artivion to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Artivion, Inc. will release its Q1 2026 financial results on May 7, 2026, after market close, providing critical financial and statistical information for investor analysis.
- Teleconference Details: The company will hold a teleconference on the release day at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin, aimed at discussing financial results in depth and addressing investor questions.
- Replay Access: A replay of the teleconference will be available approximately one hour after the event, accessible by calling 877-660-6853 or 201-612-7415, with the replay conference number being 13759187, ensuring that investors who missed the live session can still obtain relevant information.
- Company Background: Artivion is a medical device company focused on cardiac and vascular surgery, offering products such as aortic stent grafts and surgical sealants, operating in over 100 countries, and dedicated to providing solutions for the challenges faced by surgeons treating aortic diseases.
See More
